Skip to main content

Table 3 Postoperative characteristics of 109 ER-positive/HER2-negative breast cancer patients who underwent neoadjuvant chemotherapy

From: Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

  Number Percent
Pathologic stage, postoperativea
 yp0 (pathologic CR) 8 7.3
 yp1A 21 19.3
 yp1B 7 6.4
 yp2A 25 22.9
 yp2B 20 18.3
 yp3A 21 19.3
 yp3B 0 0
 yp3C 7 6.4
ER, Allred scoreb
 0–2 13 13.8
 3–5 4 4.3
 6–8 77 81.9
PR, Allred scoreb
 0–2 24 25.5
 3–5 30 31.9
 6–8 40 42.6
Ki67 index statusb, %
  < 14 67 71.3
 14–100 25 26.6
 NE 2 2.1
Lymphovascular invasionb 37 39.4
Histological gradeb,c
 G1 20 18.3
 G2 56 51.3
 G3 14 12.8
 NE 19 17.4
Recurrence 18 16.5
Local 1  
Regional 1  
Regional ➔ distant 2  
Distant 14  
Death 12 11.0
breast cancer-related 11 10.1
  1. Abbreviations: CR Complete response, ER Estrogen receptor, PR Progesterone receptor, NE Not evaluated
  2. aAJCC 8th edition
  3. bEvaluated among 94 patients who had residual tumors of the operated breast
  4. cModified Scarff-Bloom-Richardson grading system
\